Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug E7090 tested in patients with advanced solid tumors

NCT ID NCT02275910

Disease control Sponsor: Eisai Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested an experimental drug called E7090 in 40 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and check for early signs of effectiveness, especially in patients whose tumors have certain genetic changes in the FGF/FGFR pathway. The study focused on safety and tolerability, not on curing the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

40 people

The number who actually took part.

Started

Oct 2014

Finished

Sep 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Part 1and Part 2 1. Provide written informed consent 2. Male or female subjects age \>= 20 years at the time of informed consent 3. Subjects with a histological and/or cytological diagnosis of solid tumor 4. Subjects who failed standard therapies, or for which no appropriate treatment is available. 5. Subjects with Performance Status (PS) score of 0-1 established by Eastern Cooperative Oncology Group (ECOG) 6. Subjects who are expected to survive for 3 months or longer after starting administration of the investigational drug. Inclusion Criteria: Part 2 only 7. Subjects with tumor expressing genetic abnormality in FGF/FGFR (fibroblast growth factor/ fibroblast growth factor receptor)pathway. Exclusion criteria 1. Patients with brain metastasis who have clinical symptoms or requiring treatment. 2. Medical history of clinically significant cardiovascular impairment 3. Concomitant systemic infection requiring medical treatment 4. Effusion requiring drainage 5. Known intolerance to the study drug (or any of excipients) 6. Subjects whose toxicity of previous treatment has not recovered to Grade 1 or lower (except for alopecia). 7. Inability to take oral medication, or malabsorption syndrome, or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of E7090. 8. Psychiatric disorder (e.g., alcohol or drug dependency) judged to be ineligible for study entry by the investigator or subinvestigator 9. Females who are pregnant or breastfeeding 10. Any subjects who are judged by the principal investigator or the other investigators to be inappropriate as subjects in this clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tumors

Contacts and locations

Locations

  • Eisai Trial Site #1

    Nagoya, Aichi-ken, Japan

  • Eisai Trial Site #1

    Kashiwa, Chiba, Japan

  • Eisai Trial Site #1

    Matsuyama, Ehime, Japan

  • Eisai Trial Site #1

    Sapporo, Hokkaido, Japan

  • Eisai Trial Site #1

    Amagasaki, Hyōgo, Japan

  • Eisai Trial Site #1

    Tsukuba, Ibaraki, Japan

  • Eisai Trial Site #1

    Kawasaki, Kanagawa, Japan

  • Eisai Trial Site #1

    Yokohama, Kanagawa, Japan

  • Eisai Trial Site #1

    Chuo-ku, Niigata, Japan

  • Eisai Trial Site #1

    Kitaadachi, Saitama, Japan

  • Eisai Trial Site #1

    Chuo-Ku, Tokyo, Japan

  • Eisai Trial Site #1

    Koto-ku, Tokyo, Japan

  • Eisai Trial Site #1

    Chiba, Japan

  • Eisai Trial Site #1

    Fukuoka, Japan

  • Eisai Trial Site #1

    Kyoto, Japan

  • Eisai Trial Site #1

    Osaka, Japan

  • Eisai Trial Site #2

    Osaka, Japan

  • Eisai Trial Site #3

    Osaka, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.